Overview

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

Status:
Recruiting
Trial end date:
2023-06-15
Target enrollment:
Participant gender:
Summary
The purpose of the First-In-Human study is to assess safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals